Kwangdong faces damage suit

Published: 2008-05-27 06:56:00

Updated: 2008-05-27 06:56:00

Mypharm said on May 21 it would seek 10.0 billion won in compensation from Kwangdong Pharm for sales losses caused by the Kwangdong’s illegal use of a trademark “Humassen” owned by Mypharm.

Humassen is a human placenta that has been under developed by Mypharm.

“We will take legal action ag...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK